THOMAS CHU: Open Payments
NPI 1972825222 · LAS VEGAS, NV. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,059 in 80 payments from 14 companies in 2025. Trend: 2023 $1,522 · 2024 $2,034 · 2025 $2,059
Food & beverage: $1,926Education: $133
| Company | Payments | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP | 21 | $571 |
| GENZYME CORPORATION | 15 | $252 |
| Regeneron Healthcare Solutions, Inc. | 3 | $250 |
| Amgen Inc. | 14 | $219 |
| BioCryst US Sales Co., LLC | 5 | $146 |
| ARS Pharmaceuticals Operations, Inc. | 3 | $131 |
| LEO Pharma Inc. | 6 | $123 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $108 |
| SANOFI-AVENTIS U.S. LLC | 1 | $99 |
| Arcutis Biotherapeutics, Inc. | 4 | $76 |
Products named: DUPIXENT, FASENRA, TEZSPIRE, AIRSUPRA, BREZTRI, NEFFY, ADBRY, ORLADEYO.
Industry payments across NV — which companies pay providers there.
